See more : Rockley Photonics Holdings Limited (RKLY) Income Statement Analysis – Financial Results
Complete financial analysis of Editas Medicine, Inc. (EDIT) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Editas Medicine, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Vipul Limited (VIPULLTD.NS) Income Statement Analysis – Financial Results
- Kazan Public Joint Stock Company Organichesky sintez (KZOS.ME) Income Statement Analysis – Financial Results
- Empreendimentos Pague Menos S.A. (PGMN3.SA) Income Statement Analysis – Financial Results
- Jourdan Resources Inc. (JORFF) Income Statement Analysis – Financial Results
- Beijing North Star Company Limited (0588.HK) Income Statement Analysis – Financial Results
Editas Medicine, Inc. (EDIT)
About Editas Medicine, Inc.
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads to inherited childhood blindness. It also develops EDIT-102 for the treatment of Usher Syndrome 2A, which is a form of retinitis pigmentosa that also includes hearing loss; autosomal dominant retinitis pigmentosa, a progressive form of retinal degeneration; and EDIT-301 to treat sickle cell disease and transfusion-dependent beta-thalassemia. In addition, the company is developing gene-edited Natural Killer cell medicines to treat solid tumor cancers; alpha-beta T cells for multiple cancers; and gamma delta T cell therapies to treat cancer, as well as has an early discovery program to develop a therapy to treat a neurological disease. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; strategic alliance and option agreement with Allergan Pharmaceuticals International Limited to discover, develop, and commercialize new gene editing medicines for a range of ocular disorders; and research collaboration with Asklepios BioPharmaceutical, Inc. to develop a therapy to treat a neurological disease, as well as research collaboration with AskBio. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 78.12M | 19.71M | 25.54M | 90.73M | 20.53M | 31.94M | 13.73M | 6.05M | 1.63M | 0.00 | 0.00 |
| Cost of Revenue | 177.65M | 6.34M | 5.05M | 158.00M | 96.90M | 90.65M | 83.16M | 56.98M | 18.85M | 5.07M | 1.59M |
| Gross Profit | -99.53M | 13.38M | 20.49M | -67.26M | -76.37M | -58.72M | -69.43M | -50.93M | -17.22M | -5.07M | -1.59M |
| Gross Profit Ratio | -127.40% | 67.85% | 80.22% | -74.13% | -371.96% | -183.85% | -505.76% | -841.33% | -1,056.91% | 0.00% | 0.00% |
| Research & Development | 177.65M | 174.96M | 142.51M | 158.00M | 96.90M | 90.65M | 83.16M | 56.98M | 18.85M | 5.07M | 1.59M |
| General & Administrative | 69.65M | 70.70M | 76.18M | 67.58M | 64.56M | 55.01M | 50.50M | 46.26M | 18.10M | 7.65M | 3.63M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 69.65M | 70.70M | 76.18M | 67.58M | 64.56M | 55.01M | 50.50M | 46.26M | 18.10M | 7.65M | 3.63M |
| Other Expenses | 0.00 | 1.29M | -1.70M | 16.26M | -137.00K | 328.00K | 587.00K | -57.00K | -37.45M | -928.00K | 0.00 |
| Operating Expenses | 247.30M | 245.66M | 218.69M | 225.57M | 161.45M | 145.66M | 133.66M | 103.24M | 36.94M | 12.72M | 3.68M |
| Cost & Expenses | 247.30M | 245.66M | 218.69M | 225.57M | 161.45M | 145.66M | 133.66M | 103.24M | 36.94M | 12.72M | 5.27M |
| Interest Income | 17.57M | 4.23M | 2.34M | 2.61M | 7.31M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 4.23M | 0.00 | 0.00 | 0.00 | 0.00 | 978.00K | 0.00 | 143.00K | 34.00K | 0.00 |
| Depreciation & Amortization | 6.06M | 6.34M | 5.05M | 3.96M | 2.83M | 3.25M | 2.68M | 1.20M | 471.00K | 157.00K | 3.00K |
| EBITDA | -163.12M | -219.61M | -188.09M | -130.88M | -138.09M | -110.47M | -116.66M | -96.07M | -72.29M | -13.49M | -5.22M |
| EBITDA Ratio | -208.80% | -1,146.26% | -756.13% | -148.61% | -687.05% | -355.07% | -869.36% | -1,606.56% | -4,466.36% | 0.00% | 0.00% |
| Operating Income | -169.18M | -225.95M | -193.15M | -134.84M | -140.92M | -113.73M | -119.93M | -97.19M | -35.31M | -12.72M | -5.22M |
| Operating Income Ratio | -216.56% | -1,146.26% | -756.13% | -148.61% | -686.39% | -356.10% | -873.64% | -1,605.62% | -2,167.71% | 0.00% | 0.00% |
| Total Other Income/Expenses | 15.96M | 5.52M | 644.00K | 18.86M | 7.18M | 3.77M | -391.00K | 5.00K | -37.59M | -962.00K | -54.00K |
| Income Before Tax | -153.22M | -220.43M | -192.50M | -115.98M | -133.75M | -109.95M | -120.32M | -97.18M | -72.90M | -13.69M | -5.27M |
| Income Before Tax Ratio | -196.13% | -1,118.26% | -753.61% | -127.82% | -651.43% | -344.28% | -876.49% | -1,605.53% | -4,475.14% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -16.08M | -7.40M | -6.56M | -10.28M | -3.12M | -1.12M | -1.32M | -37.77M | -894.00K | 75.00K |
| Net Income | -153.22M | -204.35M | -185.11M | -109.41M | -123.47M | -109.95M | -120.32M | -97.18M | -72.90M | -13.69M | -5.35M |
| Net Income Ratio | -196.13% | -1,036.69% | -724.66% | -120.59% | -601.36% | -344.28% | -876.49% | -1,605.53% | -4,475.14% | 0.00% | 0.00% |
| EPS | -2.02 | -2.98 | -2.74 | -1.87 | -2.47 | -2.33 | -2.98 | -3.02 | -2.04 | -0.89 | -17.80 |
| EPS Diluted | -2.02 | -2.98 | -2.74 | -1.87 | -2.47 | -2.33 | -2.98 | -3.02 | -2.04 | -0.89 | -17.80 |
| Weighted Avg Shares Out | 75.97M | 68.66M | 67.62M | 58.61M | 49.98M | 47.10M | 40.32M | 32.22M | 35.70M | 15.44M | 300.48K |
| Weighted Avg Shares Out (Dil) | 75.97M | 68.66M | 67.62M | 58.61M | 49.98M | 47.10M | 40.32M | 32.22M | 35.70M | 15.44M | 300.48K |
1 Wall Street Analyst Raises Editas Medicine's Price Target by 45%. Here's Why She's Right.
Editas Medicine, Inc. (EDIT) TD Cowen 44th Annual Healthcare Conference (Transcript)
1 Beaten-Down Stock With 55% Upside, According to Wall Street
Why Editas Medicine Stock Soared as Much as 42% Higher This Week
Editas (EDIT) Q4 Earnings & Revenues Top Estimates, Stock Up
Editas Medicine: Several Catalysts For Reni-Cel In 2024 Make This A Must Watch
Editas Medicine, Inc. (EDIT) Q4 2023 Earnings Call Transcript
Editas Medicine (EDIT) Reports Q4 Loss, Tops Revenue Estimates
Editas Medicine Announces Fourth Quarter and Full Year 2023 Results and Business Updates
Editas Medicine Announces Fourth Quarter and Full Year 2023 Results Conference Call and Upcoming Investor Events
Source: https://incomestatements.info
Category: Stock Reports